BACKGROUND: Studies of adolescent and young adult (AYA) oncology end-of-life care utilization are critical because cancer is the leading cause of nonaccidental AYA death and end-of-life care contributes significantly to health care expenditures. This study was designed to determine the quantity of and disparities in inpatient utilization in the last year of life of AYAs with cancer. METHODS: The California Office of Statewide Health Planning and Development administrative discharge database, linked to death certificates, was used to perform a population-based analysis of cancer patients aged 15 to 39 years who died in 2000-2011. The number of hospital days and the inpatient costs were determined for each patient in the last year of his or her life, as were clinical and sociodemographic factors associated with high inpatient utilization. Admission patterns as death approached were also evaluated. RESULTS: The 12,883 patients were admitted for 40 days on average in the last year of life, and this cost $151,072 per patient in inpatient costs. As death approached, the admission rates and the percentage of all admissions occurring at nonspecialty centers increased. Five percent of patients used 20% of bed days in the last year (high utilizers). Factors associated with high utilization included younger age (15-30 years), Hispanic ethnicity, non-health maintenance organization insurance, and hematologic malignancies. CONCLUSIONS: AYA oncology decedents were admitted for 40 days in their last year of life. Subgroups with high utilization had distinct sociodemographic and clinical characteristics, and nonspecialty center admissions increased as death approached. This demonstrates the need for palliative care at nonspecialty centers. Future studies need to determine whether these patterns are goal-concurrent, include high utilizers, and monitor the effects of health care reform. Cancer 2018;124:1819-27. V C 2018 American Cancer Society.
INTRODUCTION
Cancer is the leading cause of nonaccidental death among adolescents and young adults (AYAs; 15-39 years old) in the United States, 1, 2 and this makes end-of-life care a critical aspect of AYA oncology. End-of-life care also has important implications for health care costs. More than 10% of the US health care budget 3 and more than 25% of Medicare claims are devoted to the last year of life. 4 However, there is a paucity of information regarding AYA oncology end-of-life care in general, and there is almost none on AYA oncology end-of-life health care utlization. 2 Utilization studies are key because of our health care expenditures and potential legislation that may limit access.
It is imperative that we determine AYA oncology patients' hospital utilization in the last year of life to determine the burden of end-of-life care on the health care system, patients, and families. This information can then be used to determine whether the utilization patterns are due to patient preference or are influenced by other factors such as provider preference and resource availability. Although there has been impressive growth in palliative care programs in the United States in the last 15 years, they are not evenly distributed; palliative care programs are more commonly housed in larger hospitals and in certain regions of the United States. 5 Determining the prevalence and patterns of health care use in the last year of life for AYAs with cancer is important so that we can begin to examine the appropriate distribution of palliative care resources. Therefore, we sought to determine AYA cancer decedents' inpatient utilization in the last year of life at a population level.
MATERIALS AND METHODS

Study Design and Oversight
We conducted a retrospective (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) population-based analysis by using the California Office of Statewide Health Planning and Development (OSHPD) private patient discharge data database, which was linked to the vital statistics death-certificate data file. The database contains data on all inpatient discharges from all California hospitals except for federal facilities and prison hospitals. OSHPD includes the following information on each discharge: age, race/ethnicity, sex, zip code of residence, payer status, length of stay, charge, and up to 24 International Classification of Diseases, Ninth Revision (ICD-9), codes. The Stanford University institutional review board and the State of California committee for the protection of human subjects approved the study. Guidelines for the reporting of studies using administrative data were followed. 6 
Study Population
The study population included patients who were 15 to 39 years old at the time of death, had died in 2000-2011, and had an oncologic ICD-9 code during a hospitalization within 6 months of death or had cancer as a deathcertificate cause of death but did not die of peripartum events or trauma; this was done to ensure that patients were dying of cancer, not with cancer ( Fig. 1 ). We could examine only patients with record linkage numbers. To have complete data and accuracy for patients, we also excluded patients who were non-California residents (n 5 204) and patients who had nonsensical information in their records such as admissions after the date of death (n 5 51). Before the removal of the last group of eligible patients due to non-California residency, nonsensical information, or potential death due to a peripartum event or trauma, there were 13,352 patients identified. Among these patients, 11,355 (85%) were identified both by a cancer ICD-9 code during an admission and by a cancer ICD-10 code on their death certificate; 785 (6%) were identified on death certificates only; and 1212 (9%) were identified by a cancer ICD-9 code only. Of the 785 without an admission with a cancer ICD-9 code, only 123 were admitted but did not have a cancer ICD-9 code during their admission; the rest were not admitted in the last 6 months of life. An initial list of oncologic ICD-9 codes was developed through the combination of the oncologic diagnosis in the Clinical Classification Software 7 and the oncologic ICD-9 codes previously used in OSHPD. 8 The death-certificate cause-of-death categories for malignant neoplasms (C00-C97) were included. Patients with potential nonmalignant conditions such as carcinomas in situ and abnormal Papanicolaou smears were excluded, as were patients who died of accidents or peripartum events. The resulting ICD-9 codes were grouped according to Surveillance, Epidemiology, and End Results AYA site categories. 9 Four oncologists independently reviewed the list for completeness and accuracy.
Study Variables
Independent variables
The sociodemographic variables included the payer status, age, sex, race and ethnicity, median household income (from the zip code median household income categorized by the 2004 federal poverty level), and distance from residence to the 1) nearest specialty center, 2) nearest hospital, and 3) last hospital used. Specialty centers were defined as Children's Oncology Group centers for those less than 18 years old and as National Cancer Institute or Children's Oncology Group centers for those 18 years old or older. Patients were classified according to Surveillance, Epidemiology, and End Results AYA categories through ICD-9 codes as described previously. The Elixhauser enhanced comorbidity score was chosen as a comorbidity index because it was developed with the OSHPD database and included oncology patients. 10, 11 Each patient scored 1 point for each nononcologic comorbidity category present during his or her final admission. 12 The payer status and comorbidities were determined from the last hospital admission before death. The location of death was determined from the death certificate or the disposition of death on a terminal admission. The remainder of the variables were determined from the death certificate unless they were missing on the death certificate; they were then abstracted from the last hospital admission.
Dependent variables
The number of unique admissions and the number of days admitted in the last year of life were calculated; admissions with ICD-9 codes for accidents (except medical errors) and peripartum care were excluded. AYA decedents with high utilization rates (ie, high utilizers), as determined by total bed days, were determined with a Pareto analysis, which is used to plot how resources are distributed throughout a population. We plotted what percentage of patients used what percentage of the total end-of-life bed days for the cohort. The corresponding Gini coefficient was calculated. Gini coefficients quantify the difference between a given distribution and the perfectly equal distribution (where each 1% of the population takes up 1% of bed days), and they are frequently used to describe a country's income distribution. A Gini coefficient of 0 corresponds to perfect equality of distribution, and a Gini coefficient of 1 indicates perfect inequality. The US income distribution has a Gini coefficient of 0.48. 13 
Cost Calculation
OSHPD includes charge but not cost information and each hospital's financial information. Hospital-specific ratios of the cost to charge ([total operating expensesother operating revenue])/total gross patient revenue) were calculated. The ratio of the cost to charge, multiplied by the charge, was then used to determine costs. 14, 15 One health maintenance organization (HMO) system did not report charges to OSHPD, so patients admitted to their system (1776 patients or 13.8% of the study population) were excluded from the cost analysis. Costs were adjusted to 2016 US dollars.
Statistical Analysis
Descriptive statistics were calculated for each of the aforementioned independent and dependent variables. The percentage of the population admitted each day was calculated for the population as a whole and for each subset of the population (eg, diagnosis and age). The percentage of admissions at specialty centers versus nonspecialty centers was calculated each month. Admissions were attributed to the month in which the admission started.
A logistic regression model was constructed to determine associations with being a high utilizer (top 5% of bed-day users). All clinical and sociodemographic variables were included in the univariate analysis. Because of concerns about collinearity, the distribution in the population, and the univariate results, the distance to the last hospital was retained for the multivariate model, but the distance to the specialty center, the distance to the closest hospital, and the urban/rural status were not. The rest of the independent variables were chosen a priori and retained for the regression analysis. For the sensitivity analysis, we also conducted a regression analysis without the location of death in case hospital death was so highly associated with increased utilization that it would skew the remainder of the results. Given how diagnosis and age are interrelated, we examined the interaction between diagnosis and age. A test-for-trend analysis was conducted for age and year of death. We present adjusted odds ratios (ORs) and 95% confidence intervals (CIs). SAS (version 9.1; SAS, Inc, Cary, North Carolina) was used.
RESULTS
Study Population Characteristics
The final study population included 12,883 patients and had the expected clinical and sociodemographic breakdowns for a cohort of terminal AYA oncology patients in California (Table 1 ). In particular, 65% of the study population was 31 years old or older, 61% of the population had solid tumors, 39% had hematologic malignancies, 95% were admitted in the last 6 months of life, and most patients (70%) were admitted to a community center at least once in their last 6 months of life. The largest racial/ ethnic group was non-Hispanic white (46%), which was followed by Hispanics (30%). Almost half of the population (48%) was publically insured. In the last year of life, hospital admissions were not evenly distributed throughout the population. In particular, 5% of the patients used 20% of the bed days, and 20% of the patients used 53% of the bed days (Fig. 2) . The associated Gini coefficient was 0.49.
Factors Associated With High Bed Utilization in the Last Year of Life
Being in the top 5% of utilizers in the last year of life was associated with younger age (OR for 15-21 years, 2.85; 95% CI, 2.27-3.58; OR for 22-30 years, 1.81; 95% CI, 1.48-2.22; reference, 31-39 years), Hispanic ethnicity (OR, 1.51; 95% CI, 1.23-1.86; reference, non-Hispanic white), and non-HMO insurance (OR for private insurance, 1.48; 95% CI, 1.08-2.04; OR for public insurance/ self-pay, 1.84; 95% CI, 1.35-2.50; reference, HMO insurance). In addition, patients with hematologic malignancies were more likely than those with solid tumors to be high utilizers (OR, 3.11; 95% CI, 2.56-3.78). Admission only at a specialty center was also associated with being a high utilizer (OR, 1.64; 95% CI, 1.36-1.97; reference, not always specialty). In addition, there were more high utilizers at the end of the study period than at the Table 2 ). Other factors associated with increased utilization were the distance from the final hospital to home and dying in the hospital. An analysis without the location of death changed the magnitude of associations (up to 20%) but did not change the direction of associations or significance. In addition, an analysis of the interaction between age and diagnosis showed that 1) at all ages, patients with hematologic malignancies were more likely to be high utilizers, and 2) for both diagnosis groups, patients who were 15 to 21 years old were more likely to be high utilizers than patients who were 22 to 29 years old, and the latter were more likely to be high utilizers than patients who were 30 to 39 years old (data not shown). However, the test-for-trend analysis showed that the age and outcome relation was not linear (data not shown).
Patterns in the Last Year of Life
As death approached, the percentage of the population admitted at a given time increased (Fig. 3) . Each subgroup analyzed (age, diagnosis, payer status, and hospital type) was distinct in detail toward the end of life, but the overall pattern of utilization for each subgroup did not change. As death approached, an increasing percentage of the admissions occurred at nonspecialty centers, with 70% of admissions occurring at nonspecialty centers in the last month before death (Fig. 3 ). There was a slight trend toward admissions occurring at hospitals closer to home (Fig. 3) . Admissions 12 months from death were a mean of 24.4 miles from the patients' home, and admissions within the last month of death were 20.3 miles from home, but this was not a statistically significant difference.
DISCUSSION
AYAs dying of cancer in California spent an average of 40 days admitted at a cost of $151,072 per patient in inpatient costs in their last year of life. This may be unwanted by families and may represent an unneeded burden on the health care system. This is the first study to determine AYA oncology patients' hospital utilization in their last year of life, and these results appear consistent with the limited existing literature: In British Columbia, oncology patients spent an average of 20 to 25 days in the hospital in their last year, 16 and in Australia, they spent just over 40 days. 17 The cost data also appear consistent with the existing literature: the average inpatient costs for a cohort of older cancer patients (average age, 62 years) in the last 6 months of life were $40,702 in 2009 dollars, or just over $45,000 in 2016 dollars (vs $124,000 in our study). 18 Because younger patients and non-HMO patients had higher utilization in the last year, our data come from a younger cohort, and the cost data lack some HMO cost information, it is not surprising that our costs are higher than those for the older cohort. What is unknown is whether this utilization is consistent with the goals of care for AYA oncology patients and how many bed days are preventable through better home services or earlier discussions about the prognosis. It has been shown that end-oflife conversations are associated with lower costs (and higher quality of life) for older cancer patients in the last week of life. 19 However, the impact of end-of-life conversations on health care earlier in the year is unknown. The number of days at home as death approaches has been suggested as a quality marker for end-of-life oncology care. 20 Therefore, it will be important to determine whether it is an appropriate AYA oncology marker and, if it is appropriate, what the benchmark should be. This AYA end-oflife cost and utilization analysis establishes a baseline that will allow monitoring as changes to the Affordable Care Act potentially limit home resources, the advent of immunotherapy changes prognostic conversations, and there is continued growth of palliative care programs. This is particularly critical to monitor because there was increased utilization later in the study period.
Not all patients and families contributed to this utilization and cost equally, as evidenced by the Gini coefficient of 0.49. There were both sociodemographic and clinical disparities in AYA oncology utilization in the last year of life that appear to drive this inequitable distribution. Sociodemographic factors associated with increased utilization included the following: younger age, Hispanic ethnicity, non-HMO insurance, and living farther from the hospital. Clinical factors associated with increased utilization included admission at specialty centers and hematologic malignancies. This is consistent with international and Medicare studies showing that end-of-life utilization varies with diagnosis, [21] [22] [23] [24] [25] [26] [27] age, 17, 26, 28 sex, 22, 24 race/ethnicity, 22, 24 socioeconomic status, 26 and comorbidities. 29 Again, it is unknown whether these disparities are due to patient preference or other factors such as provider preference, local hospice availability, or delayed end-of-life conversations, among others. Therefore, it is critical to include known high-utilizer populations in studies of end-of-life preferences to discern the underlying cause and for providers to be aware of this disparity when providing end-of-life care. This suggests that further studies of HMO systems are warranted to determine whether they are decreasing utilization (and costs) in a goalconcurrent manner. If so, the HMO model may provide ideas for potential end-of-life interventions that can decrease costs and increase end-of-life care quality. Finally, applying the Gini coefficient to determine the skewed distribution of end-of-life care is novel. It can be used to monitor the state of end-of-life care in the United States and how policies such as Affordable Care Act revisions lead to greater equality or inequality in end-of-life care.
As death approached, patients were admitted with increased frequency, and a higher percentage of those admissions occurred at nonspecialty centers. This increased utilization as death approached is not surprising and has been previously shown in Australian 22 and Canadian cancer patients. 26 However, the increased nonspecialty center utilization at the end of life is a new finding that needs to be further explored to determine how such utilization affects goal-concurrent care for AYAs dying of cancer. Some of the increased nonspecialty center utilization may be driven by patients choosing to be admitted closer to home as they near the end of life because there was a slight decrease in distance from the admission hospital to home as death approached. However, we previously showed that AYAs admitted to nonspecialty centers were more likely to receive medically intense end-of-life care (eg, cardiopulmonary resuscitation and intubation) than those admitted to specialty centers at the end of life. 30 Therefore, it appears that there is different end-of-life care at the 2 locations: community centers are less likely to see the high utilizers, but they increasingly see patients as death approaches, and the patients they see are more likely to have medically intense interventions. We need to determine whether this is consistent with patient goals: do patients at specialty centers want to spend more time in the hospital, and do patients at community centers want to have medically intense interventions? Regardless, there are important implications for clinicians and community hospital programs. Because 70% of AYA oncology admissions in the last month of life occur at nonspecialty centers, it is imperative that they have the resources and information to care for AYAs dying of cancer. We need to be sure that 1) nonspecialty center physicians are well versed in AYA end-of-life best practices, 2) palliative care programs are available at both specialty and nonspecialty centers, 3) nonspecialty centers have strong relations with local hospice agencies, and 4) there is good communication between specialty center clinicians initially caring for these patients and the nonspecialty center clinicians who are providing end-of-life care. This nonspecialty center utilization at the end of life may increase further if there are cuts to Medicaid, and this makes considerations of palliative care resource distribution and training critical.
This full population study has limitations that should be considered. It is limited to California patients, but because more than 10% of the US population resides in California and California is a diverse state, it has important implications. 31 Only patients in the linked hospital admission and death-certificate database are included in the study. Therefore, we missed patients who were not admitted at any point in their lives, patients admitted only in other states or to prison or Veterans Affairs hospitals, and patients without record linkage numbers. There were 2777 patients in the death-certificate database alone that met our inclusion criteria. If they were never admitted, it would bias our results toward more inpatient utilization and costs in the last year of life and bias our results toward a less skewed distribution of admissions in the last year of life. Because 95% of the study population was admitted in the last 6 months of life, the number of AYA oncology patients never admitted was most likely small. In addition, 44% of the 2777 unlinked patients died in the hospital; therefore, we know that almost half of those patients were admitted at some point in their lives but were not included because of admission to a nonqualifying hospital (Veterans Affairs, prison, or out of state) or the lack of a record linkage number. This is a deceasedpatient study, which has limitations in comparison with prospective studies of actively dying patients. 32 This study includes all patients who died rather than just those who died because of their disease and not treatment-related mortality. In a prospective death cohort study, we could study patients who had a sentinel event such as relapse that meant they were expected to die rather than just all patients who died, and we could examine their health care utilization once they received a terminal diagnosis. Deceased-patient studies frequently restrict themselves to patients with known terminal disease (stage IV diagnosis or relapse) to ensure that they are looking only at patients who should potentially have a palliative approach to care rather than patients who die of treatment-related mortality. However, staging and relapse information is not available in the OSHPD database. Instead, this study gives us a broad overview of end-of-life utilization for a full population, and such data are not currently available for prospective studies of death. In addition, with the emergence of immunotherapy and other new treatment paradigms, accurate prognostication is becoming increasingly challenging for clinicians and researchers. Therefore, studies that include all oncology decedents have a role. Linkages between cancer registries and administrative databases would allow us to focus on patients who were expected to die of their disease. Finally, there are other aspects of endof-life care utilization such as clinic and hospice utilization. However, more than half of end-of-life oncology costs are known to occur in the inpatient setting for older patients (and presumably more for younger patients). 18 Therefore, inpatient costs have important implications for the health care system, and inpatient utilization may not be consistent with patient wishes. Regardless of the limitations, this study establishes a methodology for studying end-of-life utilization and disparities at a population level and sets a baseline for future studies of AYA oncology end-of-life studies.
In conclusion, this population-based study in California revealed that AYA oncology decedents spent an average of 40 days in the hospital in their last year of life: more than 1 in 9 days. However, the admissions were not evenly distributed throughout the population, with more bed days for Hispanics, younger patients, those with non-HMO insurance, those living further from the hospital, and those with hematologic malignancies. In addition, the trend over time revealed that those who died after 2003 had increased utilization. It is unknown whether these disparities are due to patient preference or another factor such as provider preference or local resources. In addition, not only are increasing numbers of patients admitted as death approaches, but they are increasingly admitted at nonspecialty centers. This has important implications for how AYA end-of-life training and resources are distributed. This study both highlights groups warranting focus for further studies of end-of-life care preferences and lays the groundwork for future studies of end-of-life utilization in this vulnerable population, which will be particularly important to monitor with potential changes to US health care policy.
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